Loss-of-function of SHARPIN causes an osteopenic phenotype in mice

Endocrine

Volumn 39, Issue 2, 2011, Pages 104-112

  Xia, Tian ^a   Liang, Yanhua ^c   Ma, Junrong ^a   Li, Mi ^a   Gong, Meng ^b   Yu, Xijie ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b Maine Institute for Human Genetics & Health   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Osteoblasts; Osteoclasts; Osteopenia; SHARPIN

Indexed keywords

COLLAGEN TYPE 1; CYTOPLASM PROTEIN; MESSENGER RNA; OSTEOCALCIN; PROTEIN SHARPIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; CELL FUNCTION; CONTROLLED STUDY; GENE EXPRESSION; LOSS OF FUNCTION MUTATION; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 79953668720     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-010-9418-1     Document Type: Article

References (22)

1. Y. Daigo, I. Takayama, S.M. Ward, K.M. Sanders, M.A. Fujino, Novel human and mouse genes encoding a shank-interacting protein and its upregulation in gastric fundus of W/WV mouse. J. Gastroenterol. Hepatol. 18, 712-718 (2003)
2. A. Marchler-Bauer, J.B. Anderson, M.K. Derbyshire, C. DeWeese- Scott, N.R. Gonzales, M. Gwadz, L. Hao, S. He, D.I. Hurwitz, J.D. Jackson, Z. Ke, D. Krylov, C.J. Lanczycki, C.A. Liebert, C. Liu, F. Lu, S. Lu, G.H. Marchler, M. Mullokandov, J.S. Song, N. Thanki, R.A. Yamashita, J.J. Yin, D. Zhang, S.H. Bryant, CDD: a conserved domain database for interactive domain family analysis. Nucleic Acids Res. 35, D237-D240 (2007)
3. S. Lim, C. Sala, J. Yoon, S. Park, S. Kuroda, M. Sheng, E. Kim, Sharpin, a novel postsynaptic density protein that directly interacts with the shank family of proteins. Mol. Cell Neurosci. 17, 385-397 (2001)
4. J. Jung, J.M. Kim, B. Park, Y. Cheon, B. Lee, S.H. Choo, S.S. Koh, S. Lee, Newly identified tumor-associated role of human Sharpin. Mol. Cell. Biochem. 340, 161-167 (2010)
5. R.E. Seymour, M.G. Hasham, G.A. Cox, L.D. Shultz, H. Hogenesch, D.C. Roopenian, J.P. Sundberg, Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis. Genes Immun. 8, 416-421 (2007)
6. H. HogenEsch, M.J. Gijbels, E. Offerman, J. van Hooft, D.W. van Bekkum, C. Zurcher, A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am. J. Pathol. 143, 972-982 (1993)
7. H.I. Gallardo Torres, M.J. Gijbels, H. HegnEsch, G. Kraal, Chronic proliferative dermatitis in mice: neutrophil-endothelium interactions and the role of adhesion molecules. Pathobiology 63, 341-347 (1995)
8. M.J. Gijbels, H. HogenEsch, B. Blauw, P. Roholl, C. Zurcher, Ultrastructure of epidermis of mice with chronic proliferative dermatitis. Ultrastruct. Pathol. 19, 107-111 (1995)
9. M.J. Gijbels, C. Zurcher, G. Kraal, G.R. Elliott, H. HogenEsch, G. Schijff, H.F. Savelkoul, P.L. Bruijnzeel, Pathogenesis of skin lesions in mice with chronic proliferative dermatitis (cpdm/ cpdm). Am. J. Pathol. 148, 941-950 (1996)
10. H. HogenEsch, D. Boggess, J.P. Sundberg, Changes in keratin and filaggrin expression in the skin of CPDM mutant mice. Pathobiology 67, 45-50 (1999)
11. H. HogenEsch, S. Janke, D. Boggess, J.P. Sundberg, Absence of Peyer's patches and abnormal lymphoid architecture in chronic proliferative dermatitis (cpdm/cpdm) mice. J. Immunol. 162, 3890-3896 (1999)
12. R. Hardy, M.S. Cooper, Bone loss in inflammatory disorders. J. Endocrinol. 201, 309-320 (2009)
13. T.M. Schroeder, E.D. Jensen, J.J. Westendorf, Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res. C Embryo Today 75, 213-225 (2005)
14. K. Nakashima, X. Zhou, G. Kunkel, Z. Zhang, J.M. Deng, R.R. Behringer, B. de Crombrugghe, The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17-29 (2002)
15. C. Desbois, G. Karsenty, Osteocalcin cluster: implications for functional studies. J. Cell Biochem. 57, 379-383 (1995)
16. J. Lorenzo, M. Horowitz, Y. Choi, Osteoimmunology: interactions of the bone and immune system. Endocr. Rev. 29, 403-440 (2008)
17. L. Gilbert, X. He, P. Farmer, S. Boden, M. Kozlowski, J. Rubin, M.S. Nanes, Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 141, 3956-3964 (2000)
18. M.L. Renninger, R. Seymour, J.W. Lillard Jr., J.P. Sundberg, H. HogenEsch, Increased expression of chemokines in the skin of chronic proliferative dermatitis mutant mice. Exp. Dermatol. 14, 906-913 (2005)
19. I.M. Haeck, N.A. Hamdy, L. Timmer-de Mik, E.G. Lentjes, H.J. Verhaar, M.J. Knol, M.S. de Bruin-Weller, C.A. Bruijnzeel-Koomen, Low bone mineral density in adult patients with moderate to severe atopic dermatitis. Br. J. Dermatol. 161, 1248-1254 (2009)
20. A. Meixner, R. Zenz, H.B. Schonthaler, L. Kenner, H. Scheuch, J.M. Penninger, E.F. Wagner, Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. Nat. Cell Biol. 10, 1003-1011 (2008)
21. J.E. Onyia, B. Miller, J. Hulman, J. Liang, R. Galvin, C. Frolik, S. Chandrasekhar, A.K. Harvey, J. Bidwell, J. Herring, J.M. Hock, Proliferating cells in the primary spongiosa express osteoblastic phenotype in vitro. Bone 20, 93-100 (1997)
22. K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time qPCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408 (2001)